299 related articles for article (PubMed ID: 25171841)
1. Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity.
Kim MC; Lee YN; Hwang HS; Lee YT; Ko EJ; Jung YJ; Cho MK; Kim YJ; Lee JS; Ha SH; Kang SM
Vaccine; 2014 Oct; 32(44):5824-31. PubMed ID: 25171841
[TBL] [Abstract][Full Text] [Related]
2. Co-immunization with tandem repeat heterologous M2 extracellular proteins overcomes strain-specific protection of split vaccine against influenza A virus.
Lee YN; Kim MC; Lee YT; Kim YJ; Lee J; Kim C; Ha SH; Kang SM
Antiviral Res; 2015 Oct; 122():82-90. PubMed ID: 26248203
[TBL] [Abstract][Full Text] [Related]
3. Supplementation of H1N1pdm09 split vaccine with heterologous tandem repeat M2e5x virus-like particles confers improved cross-protection in ferrets.
Music N; Reber AJ; Kim MC; York IA; Kang SM
Vaccine; 2016 Jan; 34(4):466-473. PubMed ID: 26709639
[TBL] [Abstract][Full Text] [Related]
4. Enhancing the cross protective efficacy of live attenuated influenza virus vaccine by supplemented vaccination with M2 ectodomain virus-like particles.
Lee YT; Kim KH; Ko EJ; Kim MC; Lee YN; Hwang HS; Lee Y; Jung YJ; Kim YJ; Santos J; Perez DR; Kang SM
Virology; 2019 Mar; 529():111-121. PubMed ID: 30685658
[TBL] [Abstract][Full Text] [Related]
5. Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection.
Kim MC; Lee JW; Choi HJ; Lee YN; Hwang HS; Lee J; Kim C; Lee JS; Montemagno C; Prausnitz MR; Kang SM
J Control Release; 2015 Jul; 210():208-16. PubMed ID: 26003039
[TBL] [Abstract][Full Text] [Related]
6. Supplementation of influenza split vaccines with conserved M2 ectodomains overcomes strain specificity and provides long-term cross protection.
Kim MC; Lee YN; Ko EJ; Lee JS; Kwon YM; Hwang HS; Song JM; Song BM; Lee YJ; Choi JG; Kang HM; Quan FS; Compans RW; Kang SM
Mol Ther; 2014 Jul; 22(7):1364-1374. PubMed ID: 24590045
[TBL] [Abstract][Full Text] [Related]
7. Fc receptor is not required for inducing antibodies but plays a critical role in conferring protection after influenza M2 vaccination.
Lee YN; Lee YT; Kim MC; Hwang HS; Lee JS; Kim KH; Kang SM
Immunology; 2014 Oct; 143(2):300-9. PubMed ID: 24773389
[TBL] [Abstract][Full Text] [Related]
8. Broadly Protective CD8
Zhang H; Zheng H; Guo P; Hu L; Wang Z; Wang J; Ju Y; Meng S
J Virol; 2021 May; 95(12):. PubMed ID: 33827939
[TBL] [Abstract][Full Text] [Related]
9. Cross-protection against influenza viruses by chimeric M2e-H3 stalk protein or multi-subtype neuraminidase plus M2e virus-like particle vaccine in ferrets.
Kim KH; Bhatnagar N; Subbiah J; Liu R; Pal SS; Raha JR; Grovenstein P; Shin CH; Wang BZ; Kang SM
Virology; 2024 Jul; 595():110097. PubMed ID: 38685171
[TBL] [Abstract][Full Text] [Related]
10. Intranasal vaccination with M2e5x virus-like particles induces humoral and cellular immune responses conferring cross-protection against heterosubtypic influenza viruses.
Lee YT; Ko EJ; Lee Y; Kim KH; Kim MC; Lee YN; Kang SM
PLoS One; 2018; 13(1):e0190868. PubMed ID: 29324805
[TBL] [Abstract][Full Text] [Related]
11. A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.
Wu CY; Yeh YC; Chan JT; Yang YC; Yang JR; Liu MT; Wu HS; Hsiao PW
PLoS One; 2012; 7(8):e42363. PubMed ID: 22879951
[TBL] [Abstract][Full Text] [Related]
12. Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection.
Quan FS; Kim MC; Lee BJ; Song JM; Compans RW; Kang SM
Virology; 2012 Sep; 430(2):127-35. PubMed ID: 22658901
[TBL] [Abstract][Full Text] [Related]
13. Supplemented vaccination with tandem repeat M2e virus-like particles enhances protection against homologous and heterologous HPAI H5 viruses in chickens.
Song BM; Kang HM; Lee EK; Jung SC; Kim MC; Lee YN; Kang SM; Lee YJ
Vaccine; 2016 Jan; 34(5):678-686. PubMed ID: 26691568
[TBL] [Abstract][Full Text] [Related]
14. M2SR, a novel live single replication influenza virus vaccine, provides effective heterosubtypic protection in mice.
Sarawar S; Hatta Y; Watanabe S; Dias P; Neumann G; Kawaoka Y; Bilsel P
Vaccine; 2016 Sep; 34(42):5090-5098. PubMed ID: 27595896
[TBL] [Abstract][Full Text] [Related]
15. Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection.
Kim MC; Lee JS; Kwon YM; O E; Lee YJ; Choi JG; Wang BZ; Compans RW; Kang SM
Antiviral Res; 2013 Sep; 99(3):328-35. PubMed ID: 23811283
[TBL] [Abstract][Full Text] [Related]
16. Vaccine Efficacy Induced by 2009 Pandemic H1N1 Virus-Like Particles Differs from that Induced by Split Influenza Virus.
Lee GJ; Chu KB; Inn KS; Moon EK; Quan FS
Immunol Invest; 2020 Oct; 49(7):781-793. PubMed ID: 31774021
[TBL] [Abstract][Full Text] [Related]
17. Multiple Neuraminidase Containing Influenza Virus-like Particle Vaccines Protect Mice from Avian and Human Influenza Virus Infection.
Kang HJ; Chu KB; Yoon KW; Eom GD; Mao J; Kim MJ; Lee SH; Moon EK; Quan FS
Viruses; 2022 Feb; 14(2):. PubMed ID: 35216022
[TBL] [Abstract][Full Text] [Related]
18. Influenza Antigens NP and M2 Confer Cross Protection to BALB/c Mice against Lethal Challenge with H1N1, Pandemic H1N1 or H5N1 Influenza A Viruses.
Mytle N; Leyrer S; Inglefield JR; Harris AM; Hickey TE; Minang J; Lu H; Ma Z; Andersen H; Grubaugh ND; Guina T; Skiadopoulos MH; Lacy MJ
Viruses; 2021 Aug; 13(9):. PubMed ID: 34578289
[TBL] [Abstract][Full Text] [Related]
19. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
[TBL] [Abstract][Full Text] [Related]
20. A Novel Vaccination Strategy Mediating the Induction of Lung-Resident Memory CD8 T Cells Confers Heterosubtypic Immunity against Future Pandemic Influenza Virus.
Lee YN; Lee YT; Kim MC; Gewirtz AT; Kang SM
J Immunol; 2016 Mar; 196(6):2637-45. PubMed ID: 26864033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
